1 October 2025 - The October 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The October issue of the Schedule includes has a few new/revised listings of note: 

• Capivasertib (Truqap) - new medicine
• Dabrafenib mesylate (Tafinlar) - new indication
• Etanercept (Erelzi) - new biosimilar medicine
• Lumasiran sodium (Oxlumo) - new gene therapy
• Oestetrol with drospirenone (Nextstellis) - new combination product
• Ranibizumab (Lucentis) - new indication
• Trametinib dimethyl sulphoxide (Mekinist) - new indication

Read summary of PBS changes